Katsuhiro Masago

Dr. Katsuhiro Masago

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
YTYosuke Togashi
Yosuke Togashi
KMKatsuhiro Masago
Katsuhiro Masago
MFMasahide Fukudo
Masahide Fukudo
TTTomohiro Terada
Tomohiro Terada
SFShiro Fujita
Shiro Fujita
MMMichiaki Mishima
Michiaki Mishima
The epidermal growth factor receptor (EGFR) is recognized as an important molecular target in cancer therapy.1 x 1 Baselga, J and Arteaga, CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23: 2445–2459 Crossref | PubMed | Scopus (599) | Google Scholar See all References Erlotinib is an orally active and selective tyrosine kinase inhibitor of the EGFR (EGFR-TKI) that has demonstrated antitumor activity in patients with non-small cell lung cancer (NSCLC).2 x 2 Shepherd, FA, Rodrigues Pereira, J, Ciuleanu, T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123–132 Crossref | PubMed | Scopus (4501) | Google Scholar See all References

1 May 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
YTYosuke Togashi
Yosuke Togashi
KMKatsuhiro Masago
Katsuhiro Masago
MFMasahide Fukudo
Masahide Fukudo
TTTomohiro Terada
Tomohiro Terada
YIYasuaki Ikemi
Yasuaki Ikemi
MMMichiaki Mishima
Michiaki Mishima

6 August 2023 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
HKHiroyasu Komuro
Hiroyasu Komuro
SSShuichi Shinohara
Shuichi Shinohara
YFYasunori Fukushima
Yasunori Fukushima
ADAyako Demachi-Okamura
Ayako Demachi-Okamura
DMDaisuke Muraoka
Daisuke Muraoka
HMHirokazu Matsushita
Hirokazu Matsushita
Background: CD8+tumor infiltrating lymphocytes (TILs) are often observed in non-small cell lung cancers (NSCLC). However, the characteristics of CD8+ TILs, especially T-cell populations specific for tumor antigens, remain poorly understood. Methods: High throughput single-cell RNA sequencing and single-cell T-cell receptor (TCR) sequencing were performed on CD8+ TILs from three surgically-resected lung cancer specimens. Dimensional reduction for clustering was performed using Uniform Manifold Approximation and Projection. CD8+ TIL TCR specific for the cancer/testis antigen KK-LC-1 and for predicted neoantigens were investigated. Differentially-expressed gene analysis, Gene Set Enrichment Analysis (GSEA) and single sample GSEA was performed to characterize antigen-specific T cells. Results: A total of 6998 CD8+ T cells was analyzed, divided into 10 clusters according to their gene expression profile. An exhausted T-cell (exhausted T (Tex)) cluster characterized by the expression of ENTPD1 (CD39), TOX, PDCD1 (PD1), HAVCR2 (TIM3) and other genes, and by T-cell oligoclonality, was identified. The Tex TCR repertoire (Tex-TCRs) contained nine different TCR clonotypes recognizing five tumor antigens including a KK-LC-1 antigen and four neoantigens. By re-clustering the tumor antigen-specific T cells (n=140), it could be seen that the individual T-cell clonotypes were present on cells at different stages of differentiation and functional states even within the same Tex cluster. Stimulating these T cells with predicted cognate peptide indicated that TCR signal strength and subsequent T-cell proliferation and cytokine production was variable but always higher for neoantigens than KK-LC-1. Conclusions: Our approach focusing on T cells with an exhausted phenotype among CD8+ TILs may facilitate the identification of tumor antigens and clarify the nature of the antigen-specific T cells to specify the promising immunotherapeutic targets in patients with NSCLC.

17 December 2021 in Medicina
Verified
Journal Article
Open access
PDF file
KMKatsuhiro Masago
Katsuhiro Masago
SFShiro Fujita
Shiro Fujita
YOYuko Oya
Yuko Oya
YTYusuke Takahashi
Yusuke Takahashi
HMHirokazu Matsushita
Hirokazu Matsushita
HKHiroaki Kuroda
Hiroaki Kuroda
Background and Objectives: Panel-based next-generation sequencing (NGS) has been carried out in daily clinical settings for the diagnosis and treatment guidance of patients with non-small cell lung cancer (NSCLC). The success of genomic tests including NGS depends in large part on preparing better-quality DNA or RNA; however, there are no established operating methods for preparing genomic DNA and RNA samples. Materials and Methods: We compared the following two quantitative methods, the QubitTM and NanoDropTM, using 585 surgical specimens, 278 biopsy specimens, and 82 cell block specimens of lung cancer that were used for genetic tests, including NGS. We analyzed the success rate of the genomic tests, including NGS, which were performed with DNA and RNA with concentrations that were outliers for the Qubit Fluorometer. Results: The absolute value for DNA concentrations had a tendency to be higher when measured with NanoDropTM regardless of the type of specimen; however, this was not the case for RNA. The success rate of DNA-based genomic tests using specimens with a concentration below the lower limit of QubitTM detection was as high as approximately 96%. At less than 60%, the success rate of RNA-based genomic tests, including RT-PCR, was not as satisfactory. The success rates of the AmpliSeqTM DNA panel sequencing and RNA panel sequencing were 77.8% and 91.5%, respectively. If at least one PCR amplification product could be obtained, then all RNA-based sequencing was performed successfully. Conclusions: The concentration measurements with NanoDropTM are reliable. The success rate of NGS with samples at concentrations below the limit of detection of QubitTM was relatively higher than expected, and it is worth performing PCR-based panel sequencing, especially in cases where re-biopsy cannot be performed.

3 June 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
KMKatsuhiro Masago
Katsuhiro Masago
SFShiro Fujita
Shiro Fujita
KIKaoru Irisa
Kaoru Irisa
YKYung Hak Kim
Yung Hak Kim
MIMasataka Ichikawa
Masataka Ichikawa
MMMichiaki Mishima
Michiaki Mishima
Recently, two small-molecule kinase inhibitors targeting epidermal growth factor receptor have proven effective in the treatment of non-small cell lung cancer. There are specific activating mutations within the tyrosine kinase domain of epidermal growth factor receptor related to the sensitivity of tyrosine kinase inhibitors. However, it is unknown whether rare mutations in the N-lobe (exons 18–20) and the C-lobe (exon 21) of the epidermal growth factor receptor kinase domain other than L858R in exon 21 and the in-frame deletion in exon 19 may predict the effectiveness of epidermal growth factor receptor—tyrosine kinase inhibitors. We reported a case of non-small cell lung cancer harboring a rare epidermal growth factor somatic mutation, codon 768 AGC > ATC in exon 20 (S768I), who showed a good clinical response to gefitinib. Therefore, we may suggest that this rare mutation (S768I in exon 20) may not be an insensitive epidermal growth factor receptor somatic mutation in vivo.

14 September 2009 in Cancer Science
Verified
Journal Article
Open access
PDF file
KMKatsuhiro Masago
Katsuhiro Masago
SFShiro Fujita
Shiro Fujita
YKYung Haku Kim
Yung Haku Kim
YHYukimasa Hatachi
Yukimasa Hatachi
AFAkiko Fukuhara
Akiko Fukuhara
MMMichiaki Mishima
Michiaki Mishima
Polymorphisms have been identified in the vascular endothelial growth factor (VEGF) gene that may affect VEGF production. We hypothesized that such polymorphisms may correlate with survival outcomes among advanced‐stage non‐small‐cell lung cancer (NSCLC) patients. We evaluated the association between VEGF polymorphisms and overall survival among patients with advanced NSCLC who were treated with at least one cytotoxic regimen at Kyoto University Hospital between 2003 and 2008. We investigated the following VEGF polymorphisms: –460T > C (rs833061), +405G > C (rs2010963), +936C > T (rs3025039), –1154G > A (rs1570360), and –2578C > A (rs699947). Analyses of genotype associations with survival outcomes were performed using Cox proportional models, Kaplan–Meier methods, and the log‐rank test. There were 126 patients and 80 deaths. On a Cox regression analysis of a current and former smoker (hazards ratio [HR], 1.422; 95% confidence interval [CI], 1.111–1.859; P = 0.0046), poor performance status (PS) (HR, 2.524; 95% CI, 1.483–3.827; P = 0.0019), the VEGF –460CC genotype (HR, 1.719; 95% CI, 1.166–2.390; P = 0.0084), VEGF –1154AA and AG genotypes (HR, 1.482; 95% CI, 1.144–1.897; P = 0.0034), and VEGF –2578AA genotype (HR, 1.797; 95% CI, 1.219–2.495; P = 0.0047) had a significant prognostic effect on survival based on univariate analysis. Based on multivariate analysis of a current and former smoker (HR, 1.407; 95% CI, 1.095–1.840; P = 0.0070), poor PS (HR, 2.249; 95% CI, 1.309–3.468; P = 0.0058), and the VEGF –1154AA and AG genotypes (HR, 1.419; 95% CI, 1.033–1.901; P = 0.0316) were significant independent prognostic factors for survival. In this study, polymorphisms in VEGF may affect survival in advanced NSCLC. (Cancer Sci 2009; 100: 1917–1922)